STAT

Martin Shkreli has been sentenced. The drug industry is trying to get away scot-free

It's time for the biopharma industry to stop denying inconvenient truths, @adamfeuerstein writes
Martin Shkreli, center, with lead defense attorney Benjamin Brafman, right, at a news conference in New York in August.

On Friday, Martin Shkreli was sentenced to seven years in prison for his convictions on multiple counts of securities fraud — closing the book, for now, on the story of the drug executive who became one of the most despised people in the country.

, of course, gained notoriety for raising the price had nothing to do with that decision. But that has not stopped him from being a useful foil for pharma executives, who have done everything they can to distance themselves from the “Pharma Bro.”

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks